Proposed Learning Objectives
After participating in these activities, learners will be better able to:
- Participants will be able to evaluate the efficacy and safety of using PARP inhibitors in managing HRR-mutated metastatic prostate cancer, including potential side effects and monitoring parameters.
- Participants can review the latest guidelines and recommendations for peri-operative therapy in localized rectal cancer.
- Participants will identify the role and significance of biomarkers in early and advanced-stage non-small cell lung cancer
- Discuss current and future roles of newly approved targeted therapies in all breast cancer subtypes
- Understand the side effects of practice-changing novel therapies and their integration into community practice
- Discuss emerging strategies for patients with platinum-resistant ovarian cancer
- Discuss the optimal strategies for the use of CAR T Cell and bispecific T-cell engagers in Diffuse Large B Cell Lymphoma
- Explain how to optimize treatment selection in Multiple Myeloma, including the use of bispecific T- Cell engagers
- Identify novel treatment approaches in Acute Lymphoblastic and Acute Myeloid Leukemia
After completing this activity, participants will be able to:
- Review the recent developments in breast surgical approaches, including upfront and after neoadjuvant chemotherapy, including the decision-making approach to axillary interrogation.
- Discuss the disparities encountered and identified in the breast cancer patient.
Explain the rationale for reconstruction options post neoadjuvant chemotherapy and radiation therapy.
- Discuss updates in breast cancer imaging for earlier detection.
- Explore the understanding of subsets of aggressive breast pathology and molecular profiling.
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2 neu overexpressing, and triple-negative breast cancer.
- Review the advances in radiation therapy and outcomes, including short-course radiation therapy and de-escalation, and who may not need radiation therapy in breast conservation.
- Describe the management of HER2-positive early breast cancer in the older patient and
- Understand the psychosocial, histologic and treatment disparities of the older breast cancer patient.
- Understanding genetic mutations and approach to treatment.
- Identify the new and emerging systemic treatment options for breast cancer brain metastases beyond surgery and radiotherapy.
- Understanding the science and therapeutic options using molecular profiling for patients with breast cancer.
- Explain the mechanism of action and rationale for immunotherapy.
- Discussing the psychosocial health of the oncology health provider.
- Updates on nutritional health for patients with early and advanced breast cancer.
- Bone health and when and when not to intervene
I agree with the terms of this Agreement.
- Present current and clinically relevant information to meet the stated objectives.
- Provide a balanced view of the topic area; be objective when reporting research; and disclose unlabeled use of drugs/products where applicable.
- Discuss the safety and adverse effects of drugs/products presented.
- Inform myMedEd if you anticipate new applications or changes to the FDA status of a presented product, which may impact the planned content during the course approval period.
- Include case studies where applicable.
- Support assertions and clinical studies with references where applicable.
- Faculty members are responsible for accuracy and completeness of references as well as obtaining permission to reproduce any copyrighted materials. Provide copies of correspondence granting permission.
- myMedEd will notify faculty of the program deadline(s). The content requested must be received on or before the deadline date given.